In addition to the development of BIT225, Biotron has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus. Viroporins are encoded by many viruses and are essential for pH-dependent viral uncoating and/or assembly of infectious virus. Their role in … Continue reading Non-clinical programs